U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H4O4.Fe
Molecular Weight 171.917
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERROUS SUCCINATE

SMILES

[Fe++].[O-]C(=O)CCC([O-])=O

InChI

InChIKey=MDXRFOWKIZPNTA-UHFFFAOYSA-L
InChI=1S/C4H6O4.Fe/c5-3(6)1-2-4(7)8;/h1-2H2,(H,5,6)(H,7,8);/q;+2/p-2

HIDE SMILES / InChI
Iron(II) gluconate (also known as a ferrous gluconate) is used in the treatment of hypochromic anemia. The real problem of iron therapy is not the theoretical utilization of iron, or the reticulocyte response, or even the daily increase of hemoglobin. These are important only as they indicate the return of the patients' blood to normal in a reasonably short time without undue inconvenience. Most patients suffering from hypochromic anemia respond well to most forms of iron when administered in adequate dosage. For the patients who cannot tolerate the usual iron compounds, it is important to have a medication which is effective and which causes minimum disturbance. Ferrous gluconate is such a medicament.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
Ferro Sanol Duodenal

Approved Use

Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
PubMed

PubMed

TitleDatePubMed
FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS.
1932 Jul 1
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS.
1932 Nov 11
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A.
1932 Sep 30
THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA.
1937 Jul
[Ferrous lactate as an oral iron preparation for therapeutic use].
1954 Nov 27
[FERROUS ASPARTATE IN THERAPY].
1964 Jan 1
[Historical notes on the therapy of depression].
1986 Nov 22
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe.
1997 Oct
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice.
2009
Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study.
2009 Nov 15
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia.
2010 Dec
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis.
2011 Jun 10
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows.
2013 Jul
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
2014
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example.
2017 Jul 5
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes.
2017 Mar 13
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle.
2017 May 1
Patents

Sample Use Guides

Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
FERROUS SUCCINATE
MART.   MI   WHO-DD  
Common Name English
IRON SUCCINATE (FE(O4C4H4))
Common Name English
CEREVON
Code English
FERROMYN
Brand Name English
SUCCINIC ACID, IRON(2+) SALT (1:1)
Common Name English
Ferrous succinate [WHO-DD]
Common Name English
FERROUS SUCCINATE [MI]
Common Name English
IRON(II) SUCCINATE
Systematic Name English
FERRLECIT 2
Brand Name English
BUTANEDIOIC ACID, IRON(2+) SALT (1:1)
Common Name English
FERROUS SUCCINATE [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC B03AA06
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
WHO-VATC QB03AA06
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
Code System Code Type Description
EVMPD
SUB13875MIG
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY
DRUG BANK
DB14489
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY
RXCUI
24946
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY RxNorm
FDA UNII
818ZYK7N91
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY
SMS_ID
100000078473
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY
PUBCHEM
10464762
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY
MERCK INDEX
m5353
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY Merck Index
DRUG CENTRAL
4544
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY
CAS
10030-90-7
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY
MESH
C022943
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY
ECHA (EC/EINECS)
233-082-3
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY
ChEMBL
CHEMBL3707232
Created by admin on Fri Dec 15 18:50:42 GMT 2023 , Edited by admin on Fri Dec 15 18:50:42 GMT 2023
PRIMARY